Remote blood sampling differential protein expression associated with persistent hypertension following a...

Hypertensive disorders of pregnancy are associated with future cardiovascular risk, however, the underlying mechanisms are unclear. We sought to test the feasibility of postpartum remote blood sampling following a hypertensive disorder of pregnancy and subsequently identify differentially expressed proteins in individuals who developed hypertension.

We used data from a randomized clinical trial evaluating the feasibility of lifestyle intervention and home blood pressure monitoring of individuals with pre-pregnancy body mass index ≥25 kg/m² and new-onset hypertensive disorders of pregnancy. Blood pressure was measured at remote visits at 6 weeks and 1 year postpartum and blood microsamples were collected at the second remote visit. Mass spectrometry was used to quantify 381 proteins, from which differential expression and pathway enrichment analyses were performed to detect alterations with persistent hypertension.

Of the 100 randomized individuals, 87 completed sample collection with 85 yielding usable proteomics data. 4 proteins were differentially expressed with false discovery rate < 0.05 in individuals not taking antihypertensive medications who developed Stage 2 hypertension: Complement C4-B (C4B) and inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) levels were elevated while Afamin (AFM) and myosin light chain 6 (MYL6) levels were decreased. Pathway enrichment analysis suggests a shared function of inhibition of endopeptidases (such as Neprilysin, which degrades natriuretic peptides) in upregulated proteins and ubiquitin-proteasome mediated proteolysis activity in downregulated proteins.

Home microsampling is a promising methodology for postpartum sample collection. Serum proteomics using this approach suggest that protein homeostasis may be dysregulated in persistent hypertension following hypertensive disorders of pregnancy, providing novel candidates for future interventions.